BioSpace News Archive

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees.

Accent Therapeutics today announced an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, announced the appointment of John Nicols to Chair its Board of Directors.

Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Loïc Vincent, Ph.D., will present data from the Company’s oncogenic driver program targeting KRAS G12D, at this year’s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida, taking place April 14th – 19th.

Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention for treatment of a Periprosthetic Joint Infection occurring after Total Knee Arthroplasty.

DIACCURATE today announced that it has been selected to present new nonclinical efficacy and clinical exploratory correlative analyses of its lead compound DIACC3010 in metastatic ER+ HER2- breast cancer in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

ContraFect Corporation (Nasdaq: CFRX) announces today that the Company has been selected for an oral presentation and three poster presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 15-18, 2023 in Copenhagen, Denmark.

Mirum Pharmaceuticals, Inc. announced that Tim Walbert has been appointed to the company’s Board of Directors.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”) today announced that it has entered into purchase agreements to raise approximately $6 million from new and existing investors in a private placement of its shares of common stock.

Lunaphore and abcam (NASDAQ: ABCM) today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.